Business Plan

Fabry disease is a rare, X-linked lysosomal storage disorder caused by pathogenic variants in the GLA gene, which encodes the enzyme alpha-galactosidase A (alpha-Gal A). When alpha-Gal A activity is absent or severely reduced, a lipid substrate called globotriaosylceramide (Gb3) and its deacylated form (lyso-Gb3) accumulate progressively in the lysosomes of cells throughout the body. The consequence is a multi-system disease: patients develop chronic neuropathic pain beginning in childhood, progressive kidney dysfunction leading to renal failure in the third to fourth decade of life, hypertrophic cardiomyopathy and cardiac arrhythmias, and early stroke. Most patients also experience debilitating fatigue, gastrointestinal disturbance, and hearing loss. Life expectancy is reduced by approximately 15 to 20 years compared to the general population.

The disease affects all GLA variant types, though the clinical spectrum varies. Classic disease (near-zero enzyme activity) presents with the full multi-system burden described above. Patients with residual enzyme activity may present later but face the same progressive organ damage trajectory. Migalastat (Galafold), an oral pharmacological chaperone, is approved only for patients who carry an amenable GLA variant, which represents approximately 35 to 50% of the Fabry population. The remaining 50 to 65% have no oral option.

Prevalence estimates range from 1 in 40,000 to 1 in 117,000 live births, though the true prevalence is believed to be significantly higher due to diagnostic underrecognition, particularly in women. Approximately 5,000 to 10,000 patients are currently receiving enzyme replacement therapy (ERT) in the United States and Europe combined, representing a market generating over $1.5 billion annually for Sanofi (Fabrazyme) and Chiesi (Elfabrio) alone.

Current treatments for lysosomal storage disorders impose a severe and lifelong burden that is both clinical and personal. The problem operates on four dimensions:

These are not abstract clinical limitations. FACTS trial participants and others describe the burden in their own words:

Glafabra's Live-cel is a lentivirus-mediated gene therapy using the patient's own engineered cells to produce the missing enzyme internally. Patient cells are harvested, genetically engineered to express the corrected enzyme, and re-introduced into the patient. The modified cells engraft in the bone marrow and produce white blood cell progeny that migrate throughout the body and secrete the missing enzyme. In a process called Cross Correction, neighboring cells actively take up the secreted enzyme and use it to stop the buildup of toxic lipid metabolites.

Conventional ERT requires 26 biweekly intravenous infusions per year for life. A single GT-GLA-S03 treatment replaces 130 individual clinical infusion visits with a single outpatient procedure, repeated once every five or more years as needed. Patients are no longer required to structure their lives around their treatment schedule.

Sangamo's AAV program (isaralgagene civaparvovec, ST-920) is under a rolling BLA submission and may become the first approved gene therapy for Fabry disease. This validates the curative gene therapy market for Fabry and demonstrates FDA's willingness to approve in this indication.

AAV-based gene therapy carries a structural access barrier that receives far less attention than it deserves: approximately 40% of adults carry pre-existing neutralizing antibodies against AAV capsids acquired through prior natural AAV infections. ST-920 uses the AAV2/6 serotype, and peer-reviewed seroprevalence data show that roughly 40% of healthy US adults test positive for anti-AAV6 neutralizing antibodies (Cao et al., Gene Therapy, 2022). The STAAR trial confirmed this in practice by excluding every patient with detectable anti-AAV6 antibodies as a protocol-defined eligibility criterion. These patients are ineligible for ST-920 from the outset, before any question of efficacy arises. GT-GLA-S03 uses the patient's own modified cells rather than a viral vector; anti-capsid antibody status is irrelevant, and Live-cel reaches the full Fabry population without restriction.

A separate and distinct limitation of AAV is the neutralizing immune response that forms after treatment, making re-administration impossible. When ST-920 expression wanes after 3-5 years, a treated patient has no path back to gene therapy through that program. GT-GLA-S03 is re-administrable as needed, and as AAV-treated patients eventually experience declining expression, Live-cel will represent the only available follow-on option for that growing population. This is a future commercial opportunity that matures over time as ST-920 use expands; it is not the basis for the planned Phase 1/2 US enrollment strategy.

Orchard Therapeutics (now part of Kyowa Kirin) pioneered the same therapeutic modality as Live-cel: lentivirus-mediated hematopoietic stem cell gene correction for lysosomal storage disorders. The underlying science is closely related. The fundamental commercial and clinical difference lies in the conditioning regimen required before cell infusion.

Orchard's OTL-203 program requires full myeloablative conditioning (MAC), a busulfan-based regimen equivalent in intensity to bone marrow transplant preparation. MAC requires inpatient hospitalization, often for weeks. Even patients who technically qualify often choose not to proceed, and clinicians are frequently reluctant to recommend a regimen of this intensity for a disease that is not immediately life-threatening.

GT-GLA-S03 uses reduced-intensity conditioning (RIC) with single-agent melphalan at non-myeloablative doses, and four of five FACTS trial patients completed the entire procedure as outpatients with same-day discharge. This outpatient delivery model is not a minor incremental improvement over MAC; it is a structural advantage that reshapes the commercial opportunity in two important ways.

First, outpatient cell therapy procedures are significantly more profitable for the hospitals and cancer centers that deliver them. Without the overhead of inpatient beds, extended nursing care, and facility costs associated with MAC, the delivering institution retains a higher margin on the procedure. This makes hospital adoption and site expansion economically attractive in a way that inpatient-only protocols are not.

Second, the patient experience is fundamentally different. Same-day discharge removes one of the most significant non-disease barriers to treatment uptake: the prospect of a prolonged hospital stay. Patients who might decline a weeks-long inpatient conditioning course will meaningfully more often accept a single outpatient visit. This is not a clinical nicety; it is a patient acquisition advantage that directly expands the treated population. It is also the specific gap that ended AVROBIO's AVR-RD-01 program in 2022, and the gap that Live-cel was engineered to close.

The FACTS trial (NCT02800070), led by co-founders Jeff Medin and Ronan Foley, followed 5 patients for 5 years (PMIDs 33633114, 39794302, 36816757).

AVROBIO's AVR-RD-01 pursued the same lentiviral HSC gene correction modality but shifted to full myeloablative conditioning (MAC), which proved commercially fatal. The program was discontinued in 2022–2023. Kathy Nicholls, one of Australia's leading Fabry disease specialists, summarized the field: "I think the tech actually worked but the conditioning changes killed it. There is a big need but the landscape has changed and it would need a much more effective conditioning regimen with minimal side effects to compete." GT-GLA-S03, with its outpatient RIC protocol, is the direct answer to that assessment.

Our primary objective is to drive all assets to Phase 1/2 efficacy data to de-risk for acquisition. We are raising $16M ($1M Preseed SAFEs plus $15M Series A). Targeted acquisition of $1B to $5B by 2030 upon achievement of multi-indication Phase 1/2 data, with RMAT designation potentially enabling accelerated approval without a traditional Phase 3 trial.

Glafabra has initiated structured engagement with select leading biopharmaceutical companies that hold existing commercial infrastructure in lysosomal storage disorders. Discussions are structured across co-development, licensing, and option-to-acquire frameworks, timed to coincide with key clinical de-risking milestones.

Glafabra is not just a Fabry company; it is a platform company solving the multi-billion-dollar problem of treatment tedium without the toxicity of conditioning-based gene therapies and without the dead end of non-repeatable AAV approaches.

Live-cel replaces 26 ERT infusions a year with a single re-administrable treatment that lasts at least five years, requires no myeloablative conditioning, and applies across hundreds of enzyme deficiency disorders. One FACTS patient forgot he had Fabry for four years. Another described gaining back all that time with his family. That is the clinical standard and the commercial story.

With Sangamo's ST-920 potentially becoming the first approved Fabry gene therapy, the scale of the AAV access problem comes into sharp focus: approximately 40% of adults carry pre-existing neutralizing antibodies against the AAV6 capsid, rendering them ineligible for that therapy before a single dose is administered (Cao et al., Gene Therapy, 2022; STAAR eligibility criteria). These patients have no curative option today, carry no prior gene therapy exposure, and represent an immediate, well-defined enrollment population for the Phase 1/2 US trial. Beyond this upfront-ineligible population, as AAV-treated patients eventually experience waning expression, Live-cel is the only available follow-on, adding a durable secondary market that expands in proportion to ST-920's own commercial success.

With multiple Tier-1 biopharmaceutical companies holding established commercial assets across the lysosomal storage disorder space and facing displacement from curative alternatives, the strategic urgency for a durable, full-population, repeatable cell-based platform has never been higher. Glafabra is positioned to be the inevitable successor to the current standard of care.